{"id":1010997,"date":"2026-10-16T10:34:02","date_gmt":"2026-10-16T14:34:02","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/veracyte-secures-medicare-reimbursement-for-prosigna-breast-risk-of-recurrence-test\/"},"modified":"2026-10-16T10:34:02","modified_gmt":"2026-10-16T14:34:02","slug":"veracyte-secures-medicare-reimbursement-for-prosigna-breast-risk-of-recurrence-test","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/veracyte-secures-medicare-reimbursement-for-prosigna-breast-risk-of-recurrence-test\/","title":{"rendered":"Veracyte Secures Medicare Reimbursement for Prosigna Breast Risk of Recurrence Test"},"content":{"rendered":"

\nMilestone supports broader U.S. adoption of Prosigna and expands access for eligible patients with early-stage breast cancer
\n<\/h2>\n
\n

SOUTH SAN FRANCISCO, Oct. 16, 2026 (GLOBE NEWSWIRE) — Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced that its Prosigna\u00ae Breast Risk of Recurrence (ROR) test has received coverage for its Technical Assessment submission through Palmetto GBA\u2019s MolDX program. The decision creates a reimbursement path for eligible patients with early-stage breast cancer to receive critical genomic information to help guide their treatment.<\/p>\n

Following Prosigna\u2019s June 2026 U.S. launch, this milestone establishes a reimbursement foundation to support broader adoption of the test. Coverage is effective as of August 19, 2026, and applies to postmenopausal women with early-stage estrogen receptor positive (ER+) breast cancer who meet the applicable Medicare criteria, including stage I or II disease with 0-3 positive lymph nodes.\u00b9<\/p>\n

\u201cWe are pleased that Medicare has taken this significant step to ensure access to Prosigna for physicians and their breast cancer patients to support personalized treatment decisions,\u201d said Marc Stapley, Veracyte’s chief executive officer. \u201cSecuring Medicare reimbursement is a key step in establishing broad coverage for Prosigna. This milestone will help more patients with early-stage breast cancer, and their oncologists, make confident decisions about their treatment, including whether chemotherapy will truly benefit them.\u201d<\/p>\n

Prosigna analyzes the biology of a patient\u2019s tumor to estimate the risk that breast cancer will recur over 10 years. By combining molecular information with clinical and pathological factors, the test helps oncologists tailor treatment to the individual patient and weigh the potential benefit of chemotherapy against its short- and long-term effects.<\/p>\n

The independent, randomized phase III OPTIMA trial<\/a>, led by University College London and presented at ASCO 2026, demonstrated that for more than two-thirds of patients with clinically high-risk breast cancer, Prosigna-guided treatment could spare them chemotherapy without compromising outcomes.\u00b2<\/p>\n

Prosigna is available as a laboratory-developed test through Veracyte\u2019s CLIA-certified laboratory in San Diego. The Veracyte Access Program offers financial assistance or tailored payment plans for eligible uninsured and underinsured patients. For clinical resources and ordering information, visit www.veracyte.com\/prosigna<\/a>.<\/p>\n

\n About Veracyte<\/strong>\n <\/p>\n

Veracyte\u00a0(Nasdaq: VCYT) is a global diagnostics company with a vision to transform cancer care for patients around the world. The company\u2019s molecular tests assess the unique biology of each patient\u2019s tumor to help clinicians answer essential questions about cancer care.\u00a0Veracyte\u2019s Diagnostics Platform<\/a>\u00a0combines broad genomic and clinical data, advanced bioinformatics and AI, and a powerful evidence-generation engine to support continued\u00a0innovation and pipeline development<\/a>. The company\u2019s portfolio includes the\u00a0Afirma\u00ae Genomic Sequencing Classifier test<\/a>,\u00a0Decipher\u00ae Bladder Genomic Classifier test<\/a>,\u00a0Decipher\u00ae Prostate Genomic Classifier test<\/a>,\u00a0Prosigna\u00ae Breast Risk of Recurrence test<\/a>, and the\u00a0TrueMRD\u2122 Monitoring Test for MIBC<\/a>. For more information, visit Veracyte\u2019s\u00a0website<\/a>\u00a0or follow the company on\u00a0LinkedIn<\/a>\u00a0or\u00a0X (Twitter)<\/a>.<\/p>\n

\n Cautionary Note Regarding Forward-Looking Statements <\/strong>
\n
This press release contains forward-looking statements, including, but not limited to, statements regarding the potential clinical utility, impact, and benefits of Veracyte\u2019s Prosigna\u00ae Breast Risk of Recurrence (ROR) test; the ability of the Prosigna test to help guide treatment decisions, including whether chemotherapy may benefit a patient; the extent to which the results of the OPTIMA trial may support treatment decisions; the potential for reimbursement of the Prosigna test through Medicare to expand access to the Prosigna test for eligible patients; the potential for broader adoption of the Prosigna test and broader coverage of the Prosigna test across patient populations; and the availability of financial assistance programs and patient access to the Prosigna test. Forward-looking statements can be identified by words such as \u201cappears,\u201d \u201canticipate,\u201d \u201cintend,\u201d \u201cplan,\u201d \u201cexpect,\u201d \u201cbelieve,\u201d \u201cshould,\u201d \u201cmay,\u201d \u201cwill,\u201d \u201cenable,\u201d \u201cpositioned,\u201d \u201coffers,\u201d \u201cdesigned,\u201d \u201cultimately,\u201d and similar references to future periods. Actual results may differ materially from those projected or suggested in any forward-looking statements. These statements involve risks and uncertainties that could cause actual results to differ materially from our predictions. Additional factors that may impact these forward-looking statements can be found under the caption \u201cRisk Factors\u201d in our Annual Report on Form 10-K filed on February 26, 2026, as well as in other documents that we may file from time to time with the Securities and Exchange Commission. Copies of these documents, when available, may be found in the Investors section of our website at investor.veracyte.com. These forward-looking statements speak only as of the date hereof and, except as required by law, we specifically disclaim any obligation to update these forward-looking statements or the reasons why actual results might differ, whether as a result of new information, future events, or otherwise.\u00a0<\/p>\n

References:<\/p>\n

    \n
  1. Centers for Medicare & Medicaid Services. MolDX Breast Cancer Assay Prosigna. Local Coverage Determination L36125. https:\/\/www.cms.gov\/medicare-coverage-database\/view\/lcd.aspx?lcdid=36125<\/a><\/li>\n
  2. Stein RC, Makris A, Macpherson IR, et al. First results from the OPTIMA phase III randomized non-inferiority trial of test-directed chemotherapy in patients with high clinical risk ER-positive HER2-negative early breast cancer. J Clin Oncol. 2026;44(16_suppl):500. doi:10.1200\/JCO.2026.44.16_suppl.500.<\/li>\n<\/ol>\n

    \n Investors:<\/strong>
    \n
    Kelly Gura
    investors@veracyte.com<\/a><\/p>\n

    \n Media:<\/strong>
    \n
    Molly Cornbleet
    media@veracyte.com<\/a>
    +1 858-742-1258<\/p>\n

    \"\"
    \n
    \n \"\"\n <\/div>\n

    <\/div>\n","protected":false},"excerpt":{"rendered":"

    Milestone supports broader U.S. adoption of Prosigna and expands access for eligible patients with early-stage breast cancer SOUTH SAN FRANCISCO, Oct. 16, 2026 (GLOBE NEWSWIRE) — Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced that its Prosigna\u00ae Breast Risk of Recurrence (ROR) test has received coverage for its Technical Assessment submission through Palmetto GBA\u2019s MolDX program. The decision creates a reimbursement path for eligible patients with early-stage breast cancer to receive critical genomic information to help guide their treatment. Following Prosigna\u2019s June 2026 U.S. launch, this milestone establishes a reimbursement foundation to support broader adoption of the test. Coverage is effective as of August 19, 2026, and applies to postmenopausal women with early-stage estrogen receptor positive (ER+) … <\/p>\n

    Continue reading “Veracyte Secures Medicare Reimbursement for Prosigna Breast Risk of Recurrence Test”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-1010997","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nVeracyte Secures Medicare Reimbursement for Prosigna Breast Risk of Recurrence Test - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/veracyte-secures-medicare-reimbursement-for-prosigna-breast-risk-of-recurrence-test\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Veracyte Secures Medicare Reimbursement for Prosigna Breast Risk of Recurrence Test - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Milestone supports broader U.S. adoption of Prosigna and expands access for eligible patients with early-stage breast cancer SOUTH SAN FRANCISCO, Oct. 16, 2026 (GLOBE NEWSWIRE) — Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced that its Prosigna\u00ae Breast Risk of Recurrence (ROR) test has received coverage for its Technical Assessment submission through Palmetto GBA\u2019s MolDX program. The decision creates a reimbursement path for eligible patients with early-stage breast cancer to receive critical genomic information to help guide their treatment. Following Prosigna\u2019s June 2026 U.S. launch, this milestone establishes a reimbursement foundation to support broader adoption of the test. Coverage is effective as of August 19, 2026, and applies to postmenopausal women with early-stage estrogen receptor positive (ER+) … Continue reading "Veracyte Secures Medicare Reimbursement for Prosigna Breast Risk of Recurrence Test"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/veracyte-secures-medicare-reimbursement-for-prosigna-breast-risk-of-recurrence-test\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-10-16T14:34:02+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg0NzM4MyM3OTAwMjY1IzIwMDY2ODg=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/veracyte-secures-medicare-reimbursement-for-prosigna-breast-risk-of-recurrence-test\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/veracyte-secures-medicare-reimbursement-for-prosigna-breast-risk-of-recurrence-test\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Veracyte Secures Medicare Reimbursement for Prosigna Breast Risk of Recurrence Test\",\"datePublished\":\"2026-10-16T14:34:02+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/veracyte-secures-medicare-reimbursement-for-prosigna-breast-risk-of-recurrence-test\\\/\"},\"wordCount\":847,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/veracyte-secures-medicare-reimbursement-for-prosigna-breast-risk-of-recurrence-test\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg0NzM4MyM3OTAwMjY1IzIwMDY2ODg=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/veracyte-secures-medicare-reimbursement-for-prosigna-breast-risk-of-recurrence-test\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/veracyte-secures-medicare-reimbursement-for-prosigna-breast-risk-of-recurrence-test\\\/\",\"name\":\"Veracyte Secures Medicare Reimbursement for Prosigna Breast Risk of Recurrence Test - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/veracyte-secures-medicare-reimbursement-for-prosigna-breast-risk-of-recurrence-test\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/veracyte-secures-medicare-reimbursement-for-prosigna-breast-risk-of-recurrence-test\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg0NzM4MyM3OTAwMjY1IzIwMDY2ODg=\",\"datePublished\":\"2026-10-16T14:34:02+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/veracyte-secures-medicare-reimbursement-for-prosigna-breast-risk-of-recurrence-test\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/veracyte-secures-medicare-reimbursement-for-prosigna-breast-risk-of-recurrence-test\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/veracyte-secures-medicare-reimbursement-for-prosigna-breast-risk-of-recurrence-test\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg0NzM4MyM3OTAwMjY1IzIwMDY2ODg=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg0NzM4MyM3OTAwMjY1IzIwMDY2ODg=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/veracyte-secures-medicare-reimbursement-for-prosigna-breast-risk-of-recurrence-test\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Veracyte Secures Medicare Reimbursement for Prosigna Breast Risk of Recurrence Test\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Veracyte Secures Medicare Reimbursement for Prosigna Breast Risk of Recurrence Test - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/veracyte-secures-medicare-reimbursement-for-prosigna-breast-risk-of-recurrence-test\/","og_locale":"en_US","og_type":"article","og_title":"Veracyte Secures Medicare Reimbursement for Prosigna Breast Risk of Recurrence Test - Market Newsdesk","og_description":"Milestone supports broader U.S. adoption of Prosigna and expands access for eligible patients with early-stage breast cancer SOUTH SAN FRANCISCO, Oct. 16, 2026 (GLOBE NEWSWIRE) — Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced that its Prosigna\u00ae Breast Risk of Recurrence (ROR) test has received coverage for its Technical Assessment submission through Palmetto GBA\u2019s MolDX program. The decision creates a reimbursement path for eligible patients with early-stage breast cancer to receive critical genomic information to help guide their treatment. Following Prosigna\u2019s June 2026 U.S. launch, this milestone establishes a reimbursement foundation to support broader adoption of the test. Coverage is effective as of August 19, 2026, and applies to postmenopausal women with early-stage estrogen receptor positive (ER+) … Continue reading \"Veracyte Secures Medicare Reimbursement for Prosigna Breast Risk of Recurrence Test\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/veracyte-secures-medicare-reimbursement-for-prosigna-breast-risk-of-recurrence-test\/","og_site_name":"Market Newsdesk","article_published_time":"2026-10-16T14:34:02+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg0NzM4MyM3OTAwMjY1IzIwMDY2ODg=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/veracyte-secures-medicare-reimbursement-for-prosigna-breast-risk-of-recurrence-test\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/veracyte-secures-medicare-reimbursement-for-prosigna-breast-risk-of-recurrence-test\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Veracyte Secures Medicare Reimbursement for Prosigna Breast Risk of Recurrence Test","datePublished":"2026-10-16T14:34:02+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/veracyte-secures-medicare-reimbursement-for-prosigna-breast-risk-of-recurrence-test\/"},"wordCount":847,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/veracyte-secures-medicare-reimbursement-for-prosigna-breast-risk-of-recurrence-test\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg0NzM4MyM3OTAwMjY1IzIwMDY2ODg=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/veracyte-secures-medicare-reimbursement-for-prosigna-breast-risk-of-recurrence-test\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/veracyte-secures-medicare-reimbursement-for-prosigna-breast-risk-of-recurrence-test\/","name":"Veracyte Secures Medicare Reimbursement for Prosigna Breast Risk of Recurrence Test - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/veracyte-secures-medicare-reimbursement-for-prosigna-breast-risk-of-recurrence-test\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/veracyte-secures-medicare-reimbursement-for-prosigna-breast-risk-of-recurrence-test\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg0NzM4MyM3OTAwMjY1IzIwMDY2ODg=","datePublished":"2026-10-16T14:34:02+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/veracyte-secures-medicare-reimbursement-for-prosigna-breast-risk-of-recurrence-test\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/veracyte-secures-medicare-reimbursement-for-prosigna-breast-risk-of-recurrence-test\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/veracyte-secures-medicare-reimbursement-for-prosigna-breast-risk-of-recurrence-test\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg0NzM4MyM3OTAwMjY1IzIwMDY2ODg=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg0NzM4MyM3OTAwMjY1IzIwMDY2ODg="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/veracyte-secures-medicare-reimbursement-for-prosigna-breast-risk-of-recurrence-test\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Veracyte Secures Medicare Reimbursement for Prosigna Breast Risk of Recurrence Test"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1010997","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=1010997"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1010997\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=1010997"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=1010997"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=1010997"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}